Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699775 | 0.96 | HPGD (0.54) | HPGDCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL1163991 | 0.94 | HPGD (0.56) | HPGDCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL1163992 | 0.94 | HPGD (0.56) | HPGDCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL16424491 | 0.91 | HPGD (0.52) | HPGDCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL29012245 | 0.82 | CHRNB2 (0.55) | CTSBCTSSCTSKALDH1A1TSHR | |
| SCHEMBL5761060 | 0.82 | ALDH1A1 (0.43) | HPGDALDH1A1TSHRSMN1; SMN2ADAM10 | |
| SCHEMBL29012248 | 0.82 | CHRNB2 (0.55) | CTSBCTSSCTSKALDH1A1TSHR | |
| SCHEMBL31207070 | 0.82 | CTSB (0.57) | CTSBCTSSCTSKALDH1A1TSHR | |
| SCHEMBL5605778 | 0.82 | CTSB (0.57) | CTSBCTSSCTSKALDH1A1TSHR | |
| SCHEMBL18485318 | 0.82 | ALDH1A1 (0.43) | HPGDALDH1A1TSHRSMN1; SMN2ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878981-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3130581-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | REN, AGT, AGTR1 | HPGD 589/4885CTSB 2311/4885CTSS 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.